Refine by
Drug Discovery Process Articles & Analysis
34 news found
Integrated drug discovery services combine biology, medicinal chemistry, pharmacology and other sciences with cutting-edge technology to create new therapeutic options. As an antiviral preclinical contract research organization, Creative Diagnostics has enhanced its ability to provide a full range of services from target identification and validation, lead ...
CD ComputaBio, a pioneering provider of computational biology services, has recently introduced its advanced Computer-Aided Drug Design (CADD) services, revolutionizing the drug discovery landscape. Through the utilization of cutting-edge computational chemistry techniques, CD ComputaBio aims to streamline and enhance the process ...
Prominent within the field of computational biology, CD ComputaBio, unveils its cutting-edge Antibody Drug Design Services and Antibody Development solutions. Driven by an unwavering commitment to advancing precision medicine, the company stands at the forefront of redefining therapeutic strategies and expediting drug discovery ...
This approach is poised to revolutionize the field of drug discovery by offering researchers an efficient and cost-effective solution for identifying promising drug candidates. ...
“Throughout the manufacturing process, we focus extensively on the safety of API production on the one hand and pay attention to ensure all quality standards and cGMP requirements are met on the ...
This can lead to inaccurate predictions of a drug’s potential and extended drug development timelines. However, a number of retrospective studies confirm a high degree of similarity between the phenotype and genotype of a PDO and an original patient tumor, showing that if a drug worked on the PDO, it was 90 percent likely to work on the ...
Management will discuss the Company’s neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. They will also discuss the Company’s ongoing commercial launch strategy for IGALMI™ (dexmedetomidine) sublingual ...
Ardigen, one of the world’s leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board. Her knowledge and experience will support a deeper understanding of active cancer immunotherapies in the drug ...
ByArdigen
Valo Health, Inc ("Valo"), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that its founder & CEO, David Berry, will present at Piper Sandler's 34th Annual Healthcare Conference at The Lotte New York Palace, New York, NY, on ...
The abundance of studies on genomics and proteomics presents hundreds of new targets and opportunities for drug discovery attempts. However, it is very labor-intensive to process such “big data”. ...
Study demonstrates novel predictive models for drug metabolism to improve drug design and Optibrium and Lhasa Limited, two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and development, today announced the publication of a peer-reviewed study in the Journal of Medicinal ...
Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Agnieszka Blum, MD, PhD has joined the company’s Board of Management. She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s ...
ByArdigen
Michelle was previously Senior Marketing Manager at Healx, where she gained significant expertise in the AI drug discovery space, as well as cultivating the messaging, brand and team. Chris takes up the role of Associate Director of Business Development from KATAOKA-SS America, a laser technology manufacturer specialising in cell processing ...
As the leading expert in computer-aided drug discovery, BOC Sciences has developed compound docking technologies to facilitate the discovery of novel ligands for over 30 targets. ...
Valo Health, Inc (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, announced that David Berry, founder & CEO of Valo will present at the UBS Biotechnology Virtual Private Company Symposium on September 22, 2022 from 11:30 AM EST ...
Management will discuss the Company’s neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. They will also discuss the Company’s commercial strategy and launch of IGALMI™ (dexmedetomidine) sublingual film. ...
The project aims to advance the discovery of peptide therapeutic candidates including the most challenging of drug targets by improving overall process efficiency whilst reducing the risk and associated costs. ...
Creative Biostructure Drug Discovery, a sub-brand of Creative Biostructure that applies its expertise in structural biology and membrane proteins to the drug discovery process, has developed MagHelix™ Structural Biology and SBDD Platform that covers all the mainstream technologies needed to successfully ...
Pronalyse, a division of Creative Proteomics, is an integrated CRO company with rich experience in providing drug development services. To ensure drug identity, strength, potency, purity, and safety, Creative Proteomics Pronalyse announced the launch of therapeutic enzyme characterization services. ...
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug ...
ByIktos